OXB

News

Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.

News

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.